Detail akcie Bioline RX RSp ADR online

Business Summary: BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, BioLine RX Ltd - ADR revenues decreased 94% to $986K. Net income totaled $210K vs. loss of $6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net Income reflects Sales and marketing expenses decrease from $18.3M (expense) to $0K, Financial Expenses decrease of 78% to $1M (expense).